Therapeutic Exploratory (Phase II)

3,454 trials 1,368 recruiting

Filter these 3,454 trials by condition, country, sponsor and more.

Open in Search →

A Phase 2, Multicenter, Placebo-Controlled, Randomized, Double-Blind, 48-Week Study to Evaluate the Efficacy and Safety of Combination Thera… Ended

2023-508104-38-00 Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with L 2023-02-16
An open-label, single-arm, Phase II, multinational, multicentre study to assess the efficacy and safety of 5 years of osimertinib in partici… Ended

2023-508740-21-00 Non-Small Cell Lung Cancer 2023-02-15
Pembrolizumab and trastuzumab in combination with FLOT in the perioperative treatment of HER2-positive, localized esophagogastric adenocarci… Ended

2024-513610-34-00 HER2-positive, localized esophagogastric adenocarcinoma 2023-02-13
Roll-over study for patients who have completed a prior Novartis sponsored sabatolimab (MBG453) study and are judged by the investigator to … Ended

2024-515281-14-00 intermediate, high or very high risk MDS in adult patie 2023-02-13
A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants with Prodromal and Early Manife… Ended

2023-503928-10-00 Prodromal and Early Manifest Huntington’s Disease 2023-02-01
EFFICACY AND SAFETY TRIAL OF EPCORITAMAB WITH OR WITHOUT LENALIDOMIDE AS FIRST LINE THERAPY FOR SUBJECTS WITH DIFFUSE LARGE B-CELL LYMPHOMA. Ended

2023-504832-16-00 DIFFUSE LARGE B CELL LYMPHOMA 2023-01-24
Pembrolizumab in the Treatment of Advanced, Progressive Adrenocortical Carcinoma Ended

2024-517205-82-00 adrenocortical carcinoma 2023-01-20
Efficacy and Safety Study of Nipocalimab for Adults with Active Inflammatory Myopathies Ended

2023-505314-20-00 Active Idiopathic Inflammatory Myopathies (IIM) 2023-01-20
A Randomized Double-blind Trial to Evaluate the Efficacy, Tolerability, Safety and Dose Response of LYT-100 in Patients with Idiopathic Pulm… Ended

2024-511330-13-00 Idiopathic Pulmonary Fibrosis 2023-01-17
A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated … Ended

2023-504027-78-00 Previously Untreated Locally Advanced or Metastatic Uro 2023-01-13
A study to investigate subcutaneous isatuximab in combination with carfilzomib and dexamethasone in adult participants with relapsed and/or … Ended

2023-508870-27-00 Cancer - Relapsed/refractory multiple myeloma 2023-01-04
Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy Ended

2022-500090-13-00 Becker Muscular Dystrophy (BMD) 2022-12-29
RESTORING SENSITIVITY TO IMMUNOTHERAPY IN ADVANCED TRIPLE NEGATIVE BREAST CANCER EXPLOITING CERALASERTIB PRIMING FOLLOWED BY COMBINED DURVAL… Ended

2024-513721-23-00 ADVANCED TRIPLE NEGATIVE BREAST CANCER 2022-12-15
Pembrolizumab for locally advanced, irresectable, non-metastatic dMMR colorectal cancers. The PUMA study. Ended

2023-509707-32-00 Locally advanced, irresectable dMMR colorectal cancers 2022-12-13
An Interventional and Translational Study investigating Sotorasib in Previously Treated Locally Advanced or Metastatic NSCLC Subjects With M… Ended

2024-510837-16-00 locally-advanced and unresectable or metastatic NSCLC w 2022-12-13
PH2a, Platform Study of Novel Immunotherapy Combinations in Participants with Previously Untreated, Advanced/Metastatic NSCLC Ended

2023-505057-40-00 Lung Cancer, Non-Small Cell 2022-12-02
Towards a treatment for accelerated maturation in girls testing spiomet. Ended

2024-518675-55-00 Girls with advanced puberty and accelerated bone matura 2022-12-02
A Study to Evaluate the Pharmacodynamics, Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7204239 in Participants with Facioscapul… Ended

2022-503117-36-00 Facioscapulohumeral muscular dystrophy (FSHD) 2022-12-01
Efficacy and Safety of Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Crohn's Disease Ended

2023-504741-32-00 Moderately to Severely Active Crohn's Disease 2022-11-30
Efficacy and Safety of Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Ulcerative Colit… Ended

2023-504743-13-00 Moderately to Severely Active Ulcerative Colitis 2022-11-30
Olaparib and durvalumab (MEDI4736) in patients with metastatic pancreatic cancer and DNA Damage Repair genes alterations Ended

2024-510970-26-00 Metastatic pancreatic cancer 2022-11-28
RemiRit - Personalized immunosuppressive therapy with rituximab in the treatment of ANCA associated vasculitis - a randomized, multicenter c… Ended

2024-517881-40-00 Antineutrophil cytoplasmic antibody (ANCA)- associated 2022-11-27
Study of neoadjuvant patritumab deruxtecan with or without endocrine therapy in previously untreated patients – VALENTINE trial Ended

2023-503403-28-00 treatment naïve patients with HR+/HER2-negative high-ri 2022-11-25
A Study to Evaluate Investigational Therapies in Chronic Hepatitis D Virus Infection. Ended

2024-512203-40-00 Chronic Hepatitis D Virus (HDV) Infection 2022-11-24